The non-sterile compounding pharmacy market is witnessing remarkable growth, driven by the increasing demand for personalized medicine and advances in pharmaceutical formulation techniques. Estimated at US$ 5.97 billion in 2024, it is projected to grow to US$ 6.41 billion in 2025 and reach approximately US$ 12.11 billion by 2034, expanding at a CAGR of 7.34% between 2025 and 2034.
With applications spanning dermatology, hormonal therapies, and beyond, compounded pharmaceuticals are reshaping patient care globally. Let’s dive into key trends, regional insights, and a spotlight on leading companies in the non-sterile compounding pharmacy market.
Market Size (2024): US$ 5.97 Billion
Market Size (2025): US$ 6.41 Billion
Forecast (2034): US$ 12.11 Billion
CAGR (2025–2034): 7.34%
Rising preference for customized medicines over commercial alternatives.
Growth in dermatology and hormonal replacement therapies.
Innovations in delivery systems for improved patient adherence.
North America led with a market share of 48–52% in 2024.
Asia Pacific expected to post the fastest CAGR during 2025–2034.
Oral Solids dominated with 35–38% market share in 2024.
Topicals are forecast to grow at the highest CAGR.
Hormonal Replacement Therapy (HRT) was the leading therapeutic area in 2024, contributing 30–35% revenue.
Here’s a closer look at the major players shaping the non-sterile compounding pharmacy market, including their background, offerings, and market positioning.
About: Based in Texas, Advanced Pharmacy is a leading compounding pharmacy offering personalized medications for pain management, dermatology, and veterinary needs.
Products: Oral solutions, creams, transdermal gels.
Market Cap: Estimated mid-size player with strong regional presence in North America.
About: Avella is renowned for its specialty and compounding services, with a focus on oncology, dermatology, and ophthalmology.
Products: Topical preparations, injectables, and hormone therapies.
Market Cap: Part of UnitedHealth Group after acquisition, contributing to a multibillion-dollar network.
About: BCP specializes in bioidentical hormone replacement therapy (BHRT) and custom compounding services across the U.S.
Products: Capsules, troches, topical creams.
Market Cap: Privately held, but among the top-tier compounding service providers.
About: Serving both humans and pets, CareFirst is known for its advanced compounding labs and quality control.
Products: Oral suspensions, suppositories, transdermal patches.
Market Cap: Emerging regional player with growing influence.
About: Central Compounding Center caters to physicians and patients seeking high-quality custom formulations.
Products: Dermatology creams, hormone replacement capsules, veterinary compounds.
Market Cap: Small but rapidly expanding footprint in the Midwest U.S.
About: A division of Cipla Limited, Cipla Medpro offers non-sterile compounding solutions in South Africa and beyond.
Products: Topical dermatological formulations, oral liquids.
Market Cap: Part of Cipla’s global valuation exceeding US$ 10 billion.
About: Clinigen provides unlicensed medicines and compounding services, addressing niche therapeutic needs.
Products: Custom oral and topical formulations.
Market Cap: Approx. £1 billion (private after acquisition by Triton).
About: Specializes in veterinary compounding, serving both small and large animals.
Products: Flavored oral suspensions, transdermal gels for pets.
Market Cap: Niche player with steady growth in veterinary segment.
About: A global leader in pharmaceutical compounding with operations in over 30 countries.
Products: Dermatology creams, oral suspensions, personalized medicine kits.
Market Cap: Approx. €1.6 billion.
About: Focuses on wellness and anti-aging formulations alongside traditional compounding services.
Products: BHRT, dermatology, pediatric formulations.
Market Cap: Leading independent U.S. pharmacy.
About: Known for hormone therapy and dermatological formulations tailored to individual patient needs.
Products: Oral capsules, topical gels, sublingual tablets.
Market Cap: Mid-size U.S. player with a strong patient base.
About: Supplies high-quality APIs and excipients for compounding pharmacies, alongside their own compounding services.
Products: Customizable non-sterile medication kits.
Market Cap: Significant supplier network in North America.
About: A global supplier of pharmaceutical compounding products and equipment.
Products: Oral solutions, dermatological creams, veterinary formulations.
Market Cap: Large-scale global operations, privately held.
About: Australian pharmacy specializing in customized medications for dermatology and sports medicine.
Products: Capsules, creams, oral liquids.
Market Cap: Prominent in Oceania’s compounding market.
About: Offers innovative compounding solutions focusing on patient-specific therapies.
Products: Transdermal creams, oral suspensions, pediatric formulations.
Market Cap: Small yet growing U.S. player.
About: PCCA is a global supplier supporting compounding pharmacies with ingredients, education, and training.
Products: APIs, excipients, equipment for pharmacies.
Market Cap: Integral to compounding infrastructure worldwide.
About: Provides pharmacy services to long-term care facilities including non-sterile compounding.
Products: Oral tablets, topical solutions for institutional use.
Market Cap: Mid-size U.S. pharmacy with a focus on institutional healthcare.
Request a customized case study tailored to your business needs and gain deeper insights
into healthcare market strategies: sales@towardshealthcare.com
Q1: What is driving the growth of the non-sterile compounding pharmacy market?
A1: Growing demand for personalized medicine, advancements in compounding technologies, and rising prevalence of chronic diseases.
Q2: Which region dominates the global market?
A2: North America held the largest market share in 2024, driven by advanced healthcare infrastructure and regulatory support.
Q3: Which dosage form leads the market?
A3: Oral solids accounted for the largest market share in 2024, while topicals are expected to grow fastest.
Q4: What are some emerging trends in this market?
A4: Increased use of automation in compounding, growth of veterinary compounding, and a focus on anti-aging formulations.
Q5: Who are the key players in the market?
A5: Major companies include Fagron, Medisca, PCCA, Avella Specialty Pharmacy, and Advanced Pharmacy.
Source : https://www.towardshealthcare.com/insights/non-sterile-compounding-pharmacy-market-sizing
Invest in Our Premium Strategic Solution: https://www.towardshealthcare.com/price/5864
The global stem cell therapy market was valued at USD 490.0 million in 2024, grew to USD 613.7 million in… Read More
The global specialty medical chairs market is valued at USD 5.12 billion in 2025 and projected to reach USD 9.77… Read More
The global polio vaccine market was valued at USD 904.57 million in 2025 and is projected to reach USD 1,406.89… Read More
The global Active Pharmaceutical Ingredients (APIs) market was USD 205.98 billion in 2024, is forecast at USD 219.7 billion in… Read More
The global medical aesthetics market was valued at USD 6.25 billion in 2024 and is forecast to reach USD 8.64… Read More
The global Cell and Gene Therapy Isolator Market was USD 1.35B in 2024, rose to USD 1.52B in 2025, and… Read More